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 There are limited epilepsy mortality data from developing countries and in particular Latin America. 
We examined national epilepsy mortality data from Cuba and contrasted them with comparable 
data from England and Wales. National epilepsy mortality data for Cuba between the years 1987 
to 2010 was obtained from the Medical Records and Health Statistics Bureau of the Cuban Public 
Health Ministry (www.sld.cu/sitios/dne/ ) with the corresponding mortality data from England and 
Wales obtained from the UK Office of National Statistics (www.ons.gov.uk). Indirect 
standardisation with calculation of a standardised mortality ratio (SMR) were used to compare 
trends.  
The overall trend was of a slight decrease in mortality rates over the 23 years in Cuba, with higher 
mortality rates primarily occurring in young people. Annual age-adjusted rates were consistently 
lower in Cuba than those seen in England & Wales with the SMR ranging from 0.35 (95% CI: 0.30 
to 0.48) in 2007 to 1.00 (95% CI: 0.85 to 1.15) in 1994. 
Cuban epilepsy mortality rates are consistently lower than those of England and Wales. Reasons 
for this disparity in mortality rates are not immediately apparent but are likely to be multi-factorial. 
 
 Introduction 
 
Epilepsy is the most common serious neurological disorder affecting over 50 million people 
worldwide [1] and is associated with significant morbidity and mortality.  The incidence of epilepsy 
is estimated to be 50 per 100000 per person years but is considered to be significantly higher in 
Latin America, in part due to different aetiological factors, particularly the high prevalence of 
toxoplasmosis and other infective aetiologies [2,3]. People with epilepsy have a 2-3-fold increased 
risk of premature mortality compared to the general population, a finding which has replicated in 
multiple population studies in Europe and the US [4]. However, there is little mortality data from 
the developing countries and in particular Latin America. There has been no published epilepsy 
mortality data from Cuba apart from one recent small cohort study in people with drug resistant 
temporal lobe epilepsy5.  We have analysed national epilepsy mortality data, comparing it with 
mortality data from England & Wales during the same time period.  
 
 
Methods  
National mortality data by all types of epilepsy reported as the primary cause of death (first line) on 
the death certificate, as coded 345 (ICD9) or G40-G41 (ICD10) between 1987 to 2010 were used 
with a total of 2,518 and 21,655 deaths from Cuba and England and Wales respectively. Both 
countries used the ICD -9 classification until the year 2000 and the ICD-10 classification 
thereafter. 
Mortality data for Cuba between the years 1987 to 2010 was obtained from the Medical Records 
and Health Statistics Bureau of the Cuban Public Health Ministry (www.sld.cu/sitios/dne/ ) with the 
corresponding mortality data from England and Wales obtained from the UK Office of National 
Statistics (www.ons.gov.uk). The Cuban database is an automated public health statistical 
information system established in 1987, which are subject to periodic evaluations, both internally 
(by the National Bureau of Statistics and Information) and internationally (by the WHO). In Cuba, 
(as in England & Wales), death certificates for each patient are completed by medical doctors who 
have received specific training in order to do so. In addition, in Cuba, completed death certificates 
are routinely checked by technicians with specific qualifications in health statistics and 
management of ICD coding. The ONS database is similarly subject to regular internal validation. 
Given the relatively small numbers of epilepsy deaths in Cuba per year, examination of mortality 
trends for specific epilepsy sub-types such as focal onset epilepsy, generalised epilepsy or status 
epilepticus was not deemed feasible.  During the 23-year observation period, the population of 
Cuba increased from 10,356,301 to 11,242,161 while the population in England & Wales 
increased from 50,123,000 to 55,692,300, representing increases of 9% and 11% respectively. 
Crude mortality rates were calculated per 100,000-person year. Standardised mortality ratios 
(SMRs) with 95% confidence intervals were calculated using the population of England and Wales 
in 2010 as the standard population with calculation of mortality rates for 5-year age groups up to 
85+ years. SAS 9.3 was used for data analysis and Microsoft Excel was used to produce the 
tables and figures.  
 
Results 
The annual number of deaths in Cuba attributable to epilepsy ranged from 74 to 164 with a crude 
mortality rate of 0.71 to 1.50 per 100,000 persons-years, while the number of epilepsy deaths in 
England and Wales ranged from 743 to 1075 with a crude mortality rate of 1.45 to 2.03 per 
100,000 persons-years (Table 1). In Cuba, age-adjusted mortality rates ranged from a low of 0.39 
per 100,000 person years (95% confidence intervals CI: 0.30 to 0.48) to a peak of 1.00 per 
100,000 person years (95% CI: 0.85 to 1.15) in 1994. In general, the risk of epilepsy mortality was 
lower in Cuba compared with England & Wales.  The overall trend was of a slight decrease in 
mortality rates over the 23 years. In Cuba epilepsy mortality predominantly occurred in the young 
with the mean age of death steadily increasing during the 23 years of observation from 36 years 
(95% CI: 32.2 to 39.1) to 48 years (95% CI: 44.3 to 52.6) (eFigure 1). Mortality was significantly 
consistently higher in males across three broad age groups (0-18 years, chi-squared p<0.05; 19-
59 years, chi-squared p<0.001; 60+ years, chi-squared p<0.001) (eTable 1) and higher than that 
seen in England & Wales where figures were close to parity.  
 
Comparing epilepsy mortality in Cuba with England & Wales, annual age-adjusted rates were 
consistently lower in Cuba than those seen in England & Wales with the SMR ranging from 0.39 
(95% CI: 0.30 to 0.48) (60% lower mortality rate) in 2007 to 1.00 (95% CI: 0.85 to 1.15) in 1994 
(Figure 1). Indirect SMRs by gender are shown in eFigure 2 (males) and eFigure 3 (females).  
 
 
Discussion 
This is the first report examining national epilepsy mortality trends over 23 years in Cuba with a 
comparison with the corresponding epilepsy mortality data from England and Wales during the 
same period of observation. The main observation is that mortality rates from epilepsy are 
consistently lower in Cuba compared to England and Wales. 
 
The only previous study which examined epilepsy mortality in Cuba was in a cohort of 117 patients 
identified with refractory temporal lobe epilepsy attending a tertiary referral centre in Havana 
(National Institute of Neurology), and who were followed up over an 8-year period. During that 
time, six people died (5.1%), three of who committed suicide, one of which was a result of sudden 
unexplained death in epilepsy (SUDEP) following intentional anti-epileptic drug (AED) non-
adherence. The other three people died following status epilepticus (1), pulmonary 
thromboembolism (1) and a traffic accident (1). The only factor found to be predictive of mortality 
on multivariate analysis was the presence of a prodromal depressive disorder (p<0.0001) [5].  
 
Any analysis of mortality trends needs to be coupled with incidence and prevalence data. It is 
generally assumed that the incidence (and prevalence) of epilepsy is higher in Latin America, in 
large part to endemic infections such as toxoplasmosis, which predispose to the development of 
epilepsy [3,6]. One single study of AED prescriptions in children however suggests that the 
prevalence of epilepsy (at least in children) may be lower in Cuba than that of other Latin 
American countries. In this observational study, all prescriptions for AEDs to children in the central 
province of Camagüey were identified. 923 children receiving 977AEDs giving an estimated 
prevalence of 5.18 per 1000 children [7], which is comparable to prevalence figures seen in 
Europe and the US [4], unlike other Latin American countries where the prevalence of epilepsy is 
estimated to be higher at 8.7 to 12.4 per 1000 [8]. One reason for this may be that toxoplasmosis 
may not a significant contributor to the aetiology of epilepsy in Cuba. In a retrospective study of all 
hospital admissions to the National Institute of Neurology in Havana with epilepsy over a 25-year 
period (1974-1989), only five patients having neurocysticerosis were identified, constituting 0.01% 
of all epilepsy admissions. Moreover, of these five patients with neurocysticerosis, three were 
foreigners, with evidence that the two Cubans had acquired neurocysticerosis elsewhere [9].   
 
The consistently lower mortality epilepsy rate in Cuba compared to those in England & Wales 
requires consideration. Even in the period of highest mortality (1992-4), mortality figures were still 
lower than those seen in England & Wales and significantly lower thereafter (Figure 1). Reasons 
for this disparity are not immediately apparent.  
One of the major limitations of this study, and indeed any study of it’s type, is the validity in 
comparing mortality rates from different countries (using different datasets) and indeed with the 
method of indirect standardisation. Whilst it can be reasonably assumed that national mortality 
rates are internally consistent, thereby allowing for valid examination of national mortality trends, 
the methods of deriving these data may vary across countries, hence potentially introducing some 
bias into the comparative analysis [10]. 
This may be particularly the case comparing mortality rates from countries of different economic 
resources. However, the fact that both countries employed the same coding system (ICD-9 pre 
2000, ICD-10 post 2000) facilitates comparisons between the two databases and provides 
confidence that there are no large differences in the source data for our analysis.  
Whilst it is well recognised that the use of death certificates to estimate epilepsy mortality rates 
typically leads to a significant under-estimation of the true mortality rate attributable to epilepsy 
causes [11], there is no reason to assume that death certificate classifications in Cuba would be 
less (or more) accurate than those in the UK. Moreover, another limitation, which affects all 
mortality studies in epilepsy (unless under direct supervision), is that the recorded mortality rate 
due to epilepsy is likely to represent only a proportion of all deaths attributable to epilepsy. This is 
due to the fact that epilepsy is typically only recorded on the death certificate when epilepsy is 
judged to be the primary cause of death (such as in SUDEP or status epilepticus) when in fact the 
majority of deaths in people with epilepsy occur not as a direct result of epilepsy but rather as a 
result of epilepsy-related co-morbidities [12] [17]. Nevertheless, such deficiencies should not bias 
interpretation of secular mortality trends attributable to epilepsy unless there is reason to suspect 
that the degree of inaccuracy of recording epilepsy as the primary cause of death on death 
certificates (in either country) has changed over time [12]. In addition, the quality of data 
documented on death certificates in both Cuba and the United Kingdom (England and Wales) is 
considered high as per WHO criteria [13}. 
One potential explanation is the confounding effect of Sudden Unexpected Death in Epilepsy 
(SUDEP). Prior to the publication of the SENTINEL audit in 2002 in the UK, which highlighted the 
prevalence of SUDEP, many cases of SUDEP were recorded on the death certificate as being 
attributable to non-epilepsy causes [14]. In the scenario where cases of SUDEP in Cuba were 
consistently recorded as attributable to non-epilepsy causes of death, this would lead to a lower 
estimation than the true epilepsy mortality rate and therefore contribute to the difference in 
mortality rates between the two countries. This however is unlikely to be the complete explanation, 
particularly as it would not explain the disparity prior to the publication of the SENTINEL audit and 
the increased national awareness of SUDEP.  
 
Another potential hypothesis to explain the disparity between the mortality rates between Cuba 
and the UK may relate to differences between the two health care services. Whilst it is 
undoubtedly true that there is a significantly greater availability and numbers of anti-epileptic drugs 
in the UK, this does not forcibly translate into better care. Moreover, according to World Health 
Organisation (WHO) figures, Cuba has the highest ratio of doctors to patients in the world (7.579 
doctors per 1000 population 2014 figures) compared to only 2.806 doctors per 1000 population in 
the UK (2015 figures) [15] which may be a more protective factor. Another possibility may lie in 
differences in patients’ attitudes between the two countries, in that people with epilepsy in Cuba 
may have better AED-adherence than people in England & Wales, particularly as AED non-
adherence has been shown to result in a 3-fold increased mortality rate [16]. A final possibility is 
that people with epilepsy in England & Wales may have more co-morbidities than people with 
epilepsy in Cuba leading to a higher mortality rate [17]. 
 
In conclusion this study demonstrates, despite a transient rise in epilepsy mortality rates in Cuba 
in the early 1990s, that Cuban epilepsy mortality rate is consistently lower than that of England 
and Wales. Reasons for this disparity in mortality rates is not immediately apparent but are likely 
to be multi-factorial. This merits further study. 
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